Further research, through preclinical studies utilizing cancer models that better represent the tumor microenvironment and clinical studies assessing the levels of serum Adropin in pancreatic cancer patients, is warranted to confirm these findings and explore the relationship between serum Adropin levels, tissue ENHO expression, and patient outcomes. Here, ENHO is linked to familial pancreatic carcinoma.